Trial CTRI/2022/01/039366
Publication Thuluva S, medRxiv, 2023
Primary outcome on the report: The primary objective of the study was to assess the immunogenicity in terms of virus neutralizing antibodies (VNA) 28 days after single booster dose of CORBEVAXâ„¢ in comparison with placebo.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.